Article History
Accepted: 7 July 2022
First Online: 24 August 2022
Declarations
:
: Dr. Orringer and Grant have no conflicts or competing interests relevant to this manuscript. Dr. Tokgozoglu reports participation in a Data Safety Monitoring Board or Advisory Board for Abbott, Amgen, Novartis, Sanofi, Daiichi-Sankyo, Mylan, Pfizer. She also reports payment/honoraria from Abbott, Amgen, Daiichi Sankyo, MSD, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, and Recordati, as well as consulting fees from Abbott, Amgen, Bayer, MSD, Novartis, Sanofi, Novo Nordisk, and Daiichi Sankyo, and she reports being the Past President of the European Atherosclerosis Society and the Past President of the Turkish Society of Cardiology.
: This article does not contain any studies with human or animal subjects performed by any of the authors.